Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.
Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Inagaki T, Horiguchi J. BMC Psychiatry. 2012 Nov 29; 12:215. Epub 2012 Nov 29.